3[1]Champion RH, Burton JL, Burns DA, et al. Rook/Wilkinson/Ebling Textbook of Dermatology. 6th ed. Oxford: Blackwell Science Ltd, 1998,2085-2087.
4[3]Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin[J]. Science, 1998, 282 : 490-493.
5[4]Rutter A, Luger TA. Intravenous immunogloblin: an emerging treatment for immune-mediated skin diseases[J]. Curr (Opin In vestig Drugs, 2002, 3(5): 713-719.
6Yeung CK, Lain LK, Chan HH. The timing of intravenous immunoglobulin therapy in Steven-Johnson Syndrome and toxic epidermal necrolysis [ J ]. Clin Exp Dermatol, 2005, 30 ( 5 ) :600-602.
7Fischer M, Hamm H, Werbelauer J, Sever drug-related skin reaction: toxic epidermal necrolysis caused by carbamazepine[J]. Klin Padiatr, 2004, 216(5) : 288-293.
8Campione E, Marulli Gc, Carrozzo AM, et al. High-dose intravenous immunoglobulin for severe drug reaction: efficacy in TEN [J]. Acta Derm Venereol, 2003, 83(6) : 430-432.
